AN2 Therapeutics

Company snapshot

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM lung disease caused by M. abscessus and melioidosis,, along with programs focused on targets in oncology and infectious diseases. We are committed t

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for AN2 Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for AN2 Therapeutics.

1. Jun 5, 2026 Clinical update

   Epetraborole and matching placebo — Phase 1

2. May 26, 2026 Clinical update

   AN2-502998 — Phase 1

3. May 23, 2026 Clinical update

   Epetraborole — Phase 3

4. May 23, 2026 Clinical update

   Epetraborole — Phase 2

5. May 23, 2026 Clinical update

   Epetraborole — Phase 1

View all clinical trial activity →

• What is AN2 Therapeutics?

  AN2 Therapeutics is a pharma organization headquartered in Menlo Park, USA. It trades on NYSE under ticker ANTX. Primary therapeutic focus areas include MAC Lung Disease, Mycobacterium Abscessus Infection, Renal Insufficiency. NovaPharmaNews links 6 clinical program(s), 0 drug pr

• Is AN2 Therapeutics publicly traded?

  Yes. AN2 Therapeutics is listed with ticker ANTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does AN2 Therapeutics develop or market?

  We link 2 drug profile(s) where AN2 Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/an2-therapeutics#company-drugs.

• What are the latest developments for AN2 Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does AN2 Therapeutics focus on?

  AN2 Therapeutics focuses on MAC Lung Disease, Mycobacterium Abscessus Infection, Renal Insufficiency based on our analysis of their pipeline programs and drug development activities.